Gender effects on treatment response to interferon-beta in multiple sclerosis

2014 ◽  
Vol 130 (6) ◽  
pp. 374-379 ◽  
Author(s):  
M. Magyari ◽  
N. Koch-Henriksen ◽  
B. Laursen ◽  
P. S. Sørensen
Keyword(s):  
Multiple Sclerosis ◽  
Treatment Response ◽  
Interferon Beta ◽  
Gender Effects

IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response

2005 ◽  
Vol 163 (1-2) ◽  
pp. 165-171 ◽  
Author(s):  
Laura Leyva ◽  
Oscar Fernández ◽  
Maria Fedetz ◽  
Eva Blanco ◽  
Victoria E. Fernández ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Treatment Response ◽  
Interferon Beta

scholarly journals Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis

2020 ◽  
Vol 7 (4) ◽  
pp. e749 ◽  
Author(s):  
Marie-Christine Reinert ◽  
Pascal Benkert ◽  
Jens Wuerfel ◽  
Zuzanna Michalak ◽  
Esther Ruberte ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Disease Activity ◽  
Treatment Response ◽  
Single Molecule ◽  
Light Chain ◽  
Interferon Beta ◽  
Class Iii ◽  
Neurofilament Light Chain ◽  
Neurofilament Light ◽  
Potential Biomarker

ObjectiveTo investigate serum neurofilament light chain (sNfL) as a potential biomarker for disease activity and treatment response in pediatric patients with multiple sclerosis (MS).MethodsIn this retrospective cohort study, sNfL levels were measured in a pediatric MS cohort (n = 55, follow-up 12–105 months) and in a non-neurologic pediatric control cohort (n = 301) using a high-sensitivity single-molecule array assay. Association of sNfL levels and treatment and clinical and MRI parameters were calculated.ResultsUntreated patients had higher sNfL levels than controls (median 19.0 vs 4.6 pg/mL; CI [4.732, 6.911]), p < 0.001). sNfL levels were significantly associated with MRI activity (+9.1% per contrast-enhancing lesion, CI [1.045, 1.138], p < 0.001; +0.6% per T2-weighted lesion, CI [1.001, 1.010], p = 0.015). Higher values were associated with a relapse <90 days ago (+51.1%; CI [1.184, 1.929], p < 0.001) and a higher Expanded Disability Status Scale score (CI [1.001, 1.240], p = 0.048). In patients treated with interferon beta-1a/b (n = 27), sNfL levels declined from 14.7 to 7.9 pg/mL after 6 ± 2 months (CI [0.339, 0.603], p < 0.001). Patients with insufficient control of clinical or MRI disease activity under treatment with interferon beta-1a/b or glatiramer acetate who switched to fingolimod (n = 18) showed a reduction of sNfL levels from 16.5 to 10.0 pg/mL 6 ± 2 months after switch (CI [0.481, 0.701], p < 0.001).ConclusionssNfL is a useful biomarker for monitoring disease activity and treatment response in pediatric MS. It is most likely helpful to predict disease severity and to guide treatment decisions in patients with pediatric MS. This study provides Class III evidence that sNfL levels are associated with disease activity in pediatric MS.

Body mass index influence interferon-beta treatment response in multiple sclerosis

2015 ◽  
Vol 288 ◽  
pp. 92-97 ◽  
Author(s):  
Silje Stokke Kvistad ◽  
Kjell-Morten Myhr ◽  
Trygve Holmøy ◽  
Jūratė Šaltytė Benth ◽  
Stig Wergeland ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Body Mass Index ◽  
Treatment Response ◽  
Body Mass ◽  
Interferon Beta

scholarly journals Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort

2012 ◽  
Vol 70 (10) ◽  
pp. 774-779 ◽  
Author(s):  
Valéria Coelho Santa Rita Pereira ◽  
Fabíola Rachid Malfetano ◽  
Isabella D'Andrea Meira ◽  
Letícia Fêzer de Souza ◽  
Assuncion Martinez Liem ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Response ◽  
Treatment Response ◽  
Glatiramer Acetate ◽  
Interferon Beta ◽  
Response To Treatment ◽  
Clinical Criteria ◽  
Significant Difference ◽  
One Year ◽  
Multiple Sclerosis Patients

INTRODUCTION: Many patients with multiple sclerosis (MS) are currently receiving treatment with interferon beta (IFNb) and glatiramer acetate (GA). Identifying nonresponders patients is important to define therapy strategies. Several criteria for treatment response to IFNb and GA have been proposed. OBJECTIVE: It was to investigate the response to treatment with IFNb-1a, IFNb-1b and GA among relapsing-remitting multiple sclerosis (RRMS) patients. METHODS: We analyzed treatment response to IFNb and GA in ninety-one RRMS patients followed for at least one year. Clinical response was established by clinical criteria based on relapses, disability progression or both. RESULTS: We observed a proportion of nonresponders, ranging from 3.3 to 42.9%, depending on the stringency of the criteria used. CONCLUSIONS: Our sample of Brazilian patients with MS has similarities when compared to other studies and there was no statistically significant difference regarding age, gender, ethnicity or disease duration between responders and nonresponders.

scholarly journals Influence of APOE gene polymorphisms on interferon-beta treatment response in multiple sclerosis

2011 ◽  
Vol 26 (3) ◽  
pp. 137-142
Author(s):  
A.L. Guerrero ◽  
M.A. Tejero ◽  
F. Gutiérrez ◽  
J. Martín-Polo ◽  
F. Iglesias ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Treatment Response ◽  
Gene Polymorphisms ◽  
Interferon Beta ◽  
Apoe Gene

Pro-inflammatory cytokine and chemokine mRNA blood level in multiple sclerosis is related to treatment response and interferon-beta dose

2010 ◽  
Vol 226 (1-2) ◽  
pp. 150-157 ◽  
Author(s):  
Angele Cucci ◽  
Pierangelo Barbero ◽  
Marinella Clerico ◽  
Bruno Ferrero ◽  
Elisabetta Versino ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Treatment Response ◽  
Blood Level ◽  
Inflammatory Cytokine ◽  
Interferon Beta ◽  
Beta Dose
Sign in / Sign up

Export Citation Format

Share Document